{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:45Z","timestamp":1791156225659,"version":"4.1.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Obesity is a risk factor associated with multiple myeloma (MM) and its precursor, monoclonal gammopathy of unknown significance (MGUS). However, it is unclear how cumulative exposure to obesity affects the risk of MGUS progression to MM.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the association of cumulative exposure to excess body mass index (EBMI), defined as BMI (calculated as weight in kilograms divided by height in meters squared) greater than 25, with risk of MGUS progression to MM.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included patients with MGUS, including immunoglobin G, immunoglobin A, or light chain MGUS, from the nationwide US Veterans Health Administration database from October 1, 1999, to December 31, 2021. A published natural language processing\u2013assisted model was used to confirm diagnoses of MGUS and progression to MM. Data were analyzed from February 12 to November 4, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Cumulative EBMI was calculated by area under the curve of measured BMI subtracting the reference BMI at 25 during the first 3 years after MGUS diagnosis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was progression from MGUS to MM. Multivariable Fine-Gray time-to-competing-event analyses, with death as the competing event, were used to determine associations.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The cohort included 22\u202f429 patients with MGUS (median [IQR] age, 70.5 [63.5-77.9] years; 21\u202f613 [96.4%] male), with 8329 Black patients (37.1%) and 14\u202f100 White patients (62.9%). There were 4862 patients (21.7%) with reference range BMI (18.5 to &amp;lt;25), 7619 patients (34.0%) with BMI 25 to less than 30, and 8513 patients (38.0%) with BMI 30 or greater at the time of MGUS diagnosis. Compared with reference range BMI at MGUS diagnosis, patients with BMI 25 to less than 30 (adjusted hazard ratio [aHR], 1.17; 95% CI, 1.03-1.34) or 30 or greater (aHR, 1.27; 95% CI, 1.09-1.47) at MGUS diagnosis had higher risk of progression to MM. In patients with reference range BMI at MGUS diagnosis, each 1-unit increase of EBMI per year was associated with a 21% increase in progression risk (aHR, 1.21; 95% CI, 1.04-1.40). However, for patients with BMI 25 or greater at MGUS diagnosis, the incremental risk associated with cumulative EBMI exposure was not statistically significant.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that, for patients with BMI 18.5 to less than 25 at the time of MGUS diagnosis, cumulative exposure to BMI 25 or greater was associated with an increased risk of progression. These findings suggest that for these patients, maintaining a healthy and stable weight following MGUS diagnosis may prevent progression to MM.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.58585","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:32:32Z","timestamp":1738927952000},"page":"e2458585","source":"Crossref","is-referenced-by-count":8,"title":["Cumulative Excess Body Mass Index and MGUS Progression to Myeloma"],"prefix":"10.1001","volume":"8","author":[{"given":"Lawrence","family":"Liu","sequence":"first","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Grandhi","sequence":"additional","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Proskuriakova","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Sinai Hospital, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Thomas","sequence":"additional","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[{"name":"Department of Medicine, St Louis University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Carson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Vachon","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Quantitative Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Colditz","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Ji","sequence":"additional","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Research Service, St Louis Veterans Affairs Medical Center, St Louis, Missouri"},{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"1","key":"zoi241638r2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12885-021-08544-7","article-title":"Trends in survival from myeloma, 1990-2015: a competing risks analysis.","volume":"21","author":"Sneyd","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi241638r3","doi-asserted-by":"publisher","first-page":"17272","DOI":"10.1038\/s41598-021-96804-8","article-title":"Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016.","volume":"11","author":"Hemminki","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"zoi241638r4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40487-022-00198-0","article-title":"Healthcare costs of multiple myeloma patients with four or more prior lines of therapy, including triple-class exposure in the United States.","volume":"10","author":"Jagannath","year":"2022","journal-title":"Oncol Ther"},{"issue":"22","key":"zoi241638r5","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"3","key":"zoi241638r6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and White veterans in the United States.","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"3","key":"zoi241638r7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2013-12-539940","article-title":"Determining the significance of MGUS.","volume":"123","author":"Merlini","year":"2014","journal-title":"Blood"},{"issue":"3","key":"zoi241638r8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"issue":"22","key":"zoi241638r9","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"13","key":"zoi241638r10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi241638r11","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1055-9965.EPI-24-0490","article-title":"Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study.","volume":"33","author":"Ji","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"zoi241638r12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC Working Group.","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi241638r13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study.","volume":"109","author":"Chang","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"zoi241638r14","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"zoi241638r15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41416-024-02723-6","article-title":"Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features.","volume":"131","author":"Arnold","year":"2024","journal-title":"Br J Cancer"},{"issue":"22","key":"zoi241638r16","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood-2012-06-438606","article-title":"A prospective study of circulating adipokine levels and risk of multiple myeloma.","volume":"120","author":"Hofmann","year":"2012","journal-title":"Blood"},{"issue":"1","key":"zoi241638r17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2016.06.010","article-title":"Adipocytes contribute to the growth and progression of multiple myeloma: unraveling obesity related differences in adipocyte signaling.","volume":"380","author":"Bullwinkle","year":"2016","journal-title":"Cancer Lett"},{"issue":"2","key":"zoi241638r18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10552-008-9233-7","article-title":"Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study.","volume":"20","author":"Dalamaga","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"5","key":"zoi241638r19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1600-0609.2009.01311.x","article-title":"Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma.","volume":"83","author":"Reseland","year":"2009","journal-title":"Eur J Haematol"},{"issue":"52","key":"zoi241638r20","doi-asserted-by":"publisher","first-page":"86075","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy.","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"zoi241638r21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1118691","article-title":"Obesity and myeloma: clinical and mechanistic contributions to disease progression.","volume":"14","author":"Marques-Mourlet","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"18","key":"zoi241638r22","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1182\/bloodadvances.2023010822","article-title":"It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.","volume":"7","author":"Choa","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"zoi241638r23","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz044","article-title":"Elucidating under-studied aspects of the link between obesity and multiple myeloma: weight pattern, body shape trajectory, and body fat distribution.","volume":"3","author":"Marinac","year":"2019","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"key":"zoi241638r24","first-page":"517","article-title":"Extending the VA CPRS electronic patient record order entry system using natural language processing techniques.","author":"Lovis","year":"2000","journal-title":"Proc AMIA Symp"},{"key":"zoi241638r25","first-page":"589","article-title":"The transition to automated practitioner order entry in a teaching hospital: the VA Puget Sound experience.","author":"Payne","year":"1999","journal-title":"Proc AMIA Symp"},{"key":"zoi241638r26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1200\/JCO.2022.40.16_suppl.1557","article-title":"Natural language processing of Veterans\u2019 electronic health records to confirm diagnoses of monoclonal gammopathy of undetermined significance.","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi241638r28","first-page":"79","article-title":"IgE multiple myeloma: detection and follow-up.","volume":"3","author":"Nafr\u00eda Jim\u00e9nez","year":"2021","journal-title":"Adv Lab Med"},{"issue":"2","key":"zoi241638r29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21912","article-title":"Immunoglobulin D multiple myeloma: a rare variant.","volume":"14","author":"MacDougall","year":"2022","journal-title":"Cureus"},{"key":"zoi241638r32","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00081","article-title":"Natural language processing-assisted classification models to confirm monoclonal gammopathy of undetermined significance and progression in veterans\u2019 electronic health records.","volume":"7","author":"Wang","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"5","key":"zoi241638r33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"zoi241638r34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties.","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"446","key":"zoi241638r35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"27","key":"zoi241638r36","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data.","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"5","key":"zoi241638r37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors.","volume":"41","author":"O\u2019brien","year":"2007","journal-title":"Qual Quant"},{"issue":"4","key":"zoi241638r38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF02289756","article-title":"Point biserial correlation coefficient and its generalization.","volume":"25","author":"Gupta","year":"1960","journal-title":"Psychometrika"},{"issue":"4","key":"zoi241638r39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-022-00659-9","article-title":"Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.","volume":"12","author":"Kleinstern","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"zoi241638r40","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"zoi241638r41","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41375-023-01874-4","article-title":"Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders.","volume":"37","author":"Shah","year":"2023","journal-title":"Leukemia"},{"key":"zoi241638r42","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2023-182878","article-title":"A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS\/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial.","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"5","key":"zoi241638r43","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/pds.5579","article-title":"Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs healthcare system.","volume":"32","author":"La","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi241638r44","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S2352-3026(14)00037-4","article-title":"Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.","volume":"2","author":"Chang","year":"2015","journal-title":"Lancet Haematol"},{"issue":"12","key":"zoi241638r45","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1158\/1538-7445.AM2022-3651","article-title":"Abstract 3651: obesity, metabolic comorbidities, and lifestyle factors and their association with monoclonal gammopathies in a high-risk screened population: results of the PROMISE study.","volume":"82","author":"Lee","year":"2022","journal-title":"Cancer Res"},{"issue":"11","key":"zoi241638r46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206047","article-title":"Dietary intake is associated with risk of multiple myeloma and its precursor disease.","volume":"13","author":"Thordardottir","year":"2018","journal-title":"PLoS One"},{"key":"zoi241638r47","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1182\/blood-2023-179135","article-title":"Racial differences in the association of glucagon-like peptide 1 agonist use and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus.","volume":"142","author":"Grandhi","year":"2023","journal-title":"Blood"},{"issue":"1","key":"zoi241638r48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-023-01521-6","article-title":"The association of Agent Orange exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War era Veterans.","volume":"17","author":"Liu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"6","key":"zoi241638r49","article-title":"Association between GLP-1RA use and progression of MGUS to multiple myeloma among diabetic patients.","volume":"8","author":"Grandhi","year":"2024","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"5","key":"zoi241638r50","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/10428194.2016.1236375","article-title":"Impact of metformin on the progression of MGUS to multiple myeloma.","volume":"58","author":"Boursi","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"zoi241638r51","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1001\/archinte.160.21.3252","article-title":"Are patients at Veterans Affairs medical centers sicker: a comparative analysis of health status and medical resource use.","volume":"160","author":"Agha","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6","key":"zoi241638r52","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/archinte.158.6.626","article-title":"Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study.","volume":"158","author":"Kazis","year":"1998","journal-title":"Arch Intern Med"},{"issue":"5 Pt 2","key":"zoi241638r53","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1475-6773.2005.00448.x","article-title":"Measurement in Veterans Affairs health services research: veterans as a special population.","volume":"40","author":"Morgan","year":"2005","journal-title":"Health Serv Res"},{"key":"zoi241638r30","volume-title":"Data Quality Guidance Document: Best Practices Guide \u2013 Race Data","author":"VA Data Quality Program","year":"2012"},{"key":"zoi241638r1","unstructured":"Howlader? N, Noone? AM, Krapcho? M, , eds. SEER cancer statistics review, 1975-2016. Accessed January 2, 2025. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/index.html"},{"key":"zoi241638r27","unstructured":"Wang? M. Yu, YC, Liu, Lawrence, et al. Using Natural Language Processing Pipeline to Extract Lab Results in Veteran Health Administration\u2019s Electronic Health Records. Paper presented at the 5th Annual Institute of Clinical and Translational Sciences Symposium; May 18, 2023; St Louis, MO. Accessed August 28, 2023. https:\/\/icts.wustl.edu\/37-using-natural-language-processing-pipeline-to-extract-lab-results-in-veteran-health-administrations-electronic-health-records\/"},{"key":"zoi241638r31","unstructured":"National Heart, Lung, and Blood Institute. Calculate your body mass index. Accessed December 30, 2022. https:\/\/www.nhlbi.nih.gov\/health\/educational\/lose_wt\/BMI\/bmicalc.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830028\/liu_2025_oi_241638_1738258967.34863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:32:41Z","timestamp":1738927961000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.58585","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}